Pentoxifylline Dose Optimization in Neonatal Sepsis

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 12, 2020

Primary Completion Date

October 31, 2022

Study Completion Date

December 31, 2022

Conditions
Neonatal Late Onset Sepsis
Interventions
DRUG

Pentoxifylline

The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.

Trial Locations (2)

3000CB

Erasmus MC Sophia Children's Hospital, Rotterdam

61-701

University Hospital Poznan, Poznan

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER